Search Results
10
Everything
Search Filters
Organization
F. Hoffmann-La Roche Ltd
Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference
March 17, 2025 02:00 ET
|
F. Hoffmann-La Roche Ltd
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of individuals with Types 2 or 3 spinal muscular atrophy (SMA)Late-breaking...
Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity
March 12, 2025 02:00 ET
|
F. Hoffmann-La Roche Ltd
Agreement allows for a range of potentially best-in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT 388Collaboration will complement Roche's...
Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston
March 07, 2025 01:00 ET
|
F. Hoffmann-La Roche Ltd
The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data science and AI specialists to drive innovation in...
FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
March 05, 2025 01:00 ET
|
F. Hoffmann-La Roche Ltd
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal response benefit1 The filing application is based on data from the phase III...
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
March 02, 2025 17:00 ET
|
F. Hoffmann-La Roche Ltd
First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured as late-breakers at the 2025 AAAAI Annual MeetingXolair is the only US FDA-approved medicine to reduce...
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
February 28, 2025 08:15 ET
|
F. Hoffmann-La Roche Ltd
Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study1,2 DLBCL—an aggressive disease with a high risk of progression—remains an area of high...
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
February 20, 2025 13:30 ET
|
F. Hoffmann-La Roche Ltd
Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer,...
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
February 12, 2025 11:45 ET
|
F. Hoffmann-La Roche Ltd
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and...
New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis
February 07, 2025 03:45 ET
|
F. Hoffmann-La Roche Ltd
Nearly half of patients on Gazyva/Gazyvaro plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvement, compared to standard...
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
February 04, 2025 11:45 ET
|
F. Hoffmann-La Roche Ltd
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)With as few as two treatments per year, Susvimo...